Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect and safety of semaglutide 2.4 mg once weekly in subjects with overweight or obesity
2017-003436-36Phase 3Unknown
- Sponsor
- Novo Nordisk
- Start
- Feb 2018
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obesity and Overweight comparing Semaglutide 2.4 mg once weekly with Placebo once weekly (2 arms). Primary endpoint: Change in body weight (%). Status: unknown.
02
Drugs
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on 2017-003436-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003436-36.